作者
Anna Tavridou, Loukas Kaklamanis, Apostolos Papalois, Angeliki P Kourounakis, Eleni A Rekka, Panos N Kourounakis, Avgui Charalambous, Vangelis G Manolopoulos
发表日期
2007/12/1
期刊
Journal of Pharmacology and Experimental Therapeutics
卷号
323
期号
3
页码范围
794-804
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide] inhibits squalene synthase and lipid biosynthesis and possesses antioxidant properties. We hypothesized that EP2306 can effectively modify circulating lipids and reduce atherosclerosis in the cholesterol-fed rabbit. Animals were fed a high-cholesterol diet for 4 weeks followed by 4 (phase 1 and 2) or 12 weeks (phase 3) of drug treatment while on high-cholesterol diet. In phase 1, the dose-effect relationship of EP2306 on lipids and atherosclerosis was established, and its most effective dose was determined (2 mg/kg). This dose reduced significantly total cholesterol (512 ± 96 mg/dl before versus 320 ± 124 mg/dl after treatment, p < 0.05) and atherosclerotic lesions compared with control animals. In phase 2, the effects of 2 mg/kg EP2306, 2.5 mg/kg simvastatin, and their combination were assessed. Although no significant effect on lipid …
引用总数
20082009201020112012201320142015201620172018201920202021202220235654136212111